[1] Eslam M, Sanyal AJ, George J, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology, 2020, 158: 1999-2014.e1. [2] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol, 2020, 73: 202-209. [3] Hamaguchi M, Kojima T, Takeda N, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol, 2007, 13: 1579-1584. [4] Mellinger JL, Pencina KM, Massaro JM, et al. Hepatic steatosis and cardiovascular disease outcomes: an analysis of the Framingham Heart Study. J Hepatol, 2015, 63: 470-476. [5] Mori T, Yoshioka K, Tanno Y. Non-alcoholic fatty liver disease frequency and associated factors at admission of acute stroke. Hepatol Int, 2022, 16: 81-88. [6] Liang Y, Chen H, Liu Y, et al. Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: a 4.6-year cohort study in China. J Clin Endocrinol Metab, 2022, 107: 88-97. [7] Liu HH, Cao YX, Jin JL, et al. Metabolic-associated fatty liver disease and major adverse cardiac events in patients with chronic coronary syndrome: a matched case-control study. Hepatol Int, 2021, 15: 1337-1346. [8] Iasonos A, Schrag D, Raj GV, et al. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol, 2008, 26: 1364-1370. [9] Xin F, Fu L, Yang B, et al. Development and validation of a nomogram for predicting stroke risk in rheumatoid arthritis patients. Aging (Albany NY), 2021, 13: 15061-15077. [10] Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 2018, 67: 328-357. [11] Nguyen VH, Le MH, Cheung RC, et al. Differential clinical characteristics and mortality outcomes in persons with NAFLD and/or MAFLD. Clin Gastroenterol Hepatol, 2021, 19: 2172-2181.e6. [12] Lim GEH, Tang A, Ng CH, et al. An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD. Clin Gastroenterol Hepatol, 2021, S1542-3565(21)01276-3. Online ahead of print. [13] 薛芮, 范建高. 代谢相关脂肪性肝病新定义的国际专家共识简介. 实用肝脏病杂志, 2020, 23: S55-S58. [14] 陈源文. 脂肪肝是否增加患心血管疾病风险. 肝脏, 2017, 22: 10,14. [15] Baratta F, Pastori D, Angelico F, et al. Nonalcoholic fatty liver disease and fibrosis associated with increased risk of cardiovascular events in a prospective study. Clin Gastroenterol Hepatol, 2020, 18: 2324-2331.e4. [16] Sun D, Jin Y, Wang T, et al. MAFLD and risk of CKD. Metabolism, 2021, 115: 154433. |